The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is a key predictor of temozolomide chemosensitivity (2), whereas isocitrate dehydrogenase (IDH) mutations are strongly associated with molecular typing of gliomas and good prognosis (3). Here, IDH2 is linked to glioma.